Back to School: How biopharma can reboot drug development. Access exclusive analysis here

LBR-101: Phase I data

Pooled data from 5 double-blind, placebo-controlled Phase I trials in 94 healthy volunteers showed that single doses of 0.2-2,000 mg IV

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE